Alliance Global raised the firm’s price target on Pelthos Therapeutics (PTHS) to $75 from $60 and keeps a Buy rating on the shares. The company’s Q3 report showed progress on the Zelsuvmi launch, the analyst tells investors in a research note. The firm says Zelsuvmi is the only use-at-home treatment for water warts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTHS: